Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

e United States, Europe, Latin America and Asia have agreed to participate, providing the potential to identify meaningful information about regional or country-specific differences in patient demographics and treatment decisions.

Atrial fibrillation, characterized by an irregular heartbeat, can cause blood clots to form in the heart that can travel to the brain and cause a stroke. An estimated 2.3 million Americans are living with atrial fibrillation, and the prevalence is expected to increase to 5.6 million by 2050. Non-valvular atrial fibrillation, which accounts for up to 95 percent of diagnosed cases of atrial fibrillation, refers to cases of atrial fibrillation without rheumatic mitral valve disease, prosthetic heart valve or valve repair, according to the 2006 ACC/AHA/ESC guidelines. Atrial fibrillation increases the risk of stroke nearly five times and is associated with up to 15 percent of all strokes in the U.S. Atrial fibrillation imposes a substantial economic burden to the healthcare system, specifically the high costs associated with stroke.

In the pivotal RE-LY® trial, PRADAXA 150mg taken twice daily significantly reduced stroke and systemic embolism in patients with NVAF by 35 percent beyond the reduction achieved with warfarin dosed to target INR 2.0 to 3.0 (median TTR 67%). PRADAXA 150mg also was shown to significantly reduce both ischemic and hemorrhagic stroke compared to warfarin in patients with NVAF. Effects of PRADAXA compared to warfarin were more apparent in patients with lower levels of INR control.

*All trademarks are registered trademarks of their respective owners.

About Pradaxa® (dabigatran etexilate mesylate) Capsules

Indications and Usage

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass Vascular ... on innovating lifesaving devices and methods for vascular ... in Series A financing, which was led by ... the deal will allow Bluegrass Vascular to obtain ... System, enhance manufacturing capabilities, and proceed with US ...
(Date:7/30/2014)... , July 30, 2014 ... CUDA programming expertise to big data, aerospace and ... eInfochips, a leading engineering R&D services company, ... develop NVIDIA GPU-powered solutions for aerospace and ... computing (HPC), industrial , and ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Dec. 5, 2011   New product launches are continually ... critical for organizations to balance the dueling goals of containing ... executives face is determining how much to invest, and how ... budget for primary care launch is spent before ...
... 5, 2011 Technology is revolutionizing healthcare — making ... lowering the cost of care. AT&T ,s* new ... — is designed to do just that. The 2011 ... awarded to AT&T for its approach to mHealth, recognizing ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 3Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 4
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... 2014 Visitors to our region recognize ... to ensure its protection. Bob Kiesendahl, one of the ... the Delaware Highlands Conservancy for donations collected through participation ... donations add up fast, as visitors welcome the opportunity ... River Region. , The Kiesendahl family has owned Woodloch ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... DRE Medical — a leading medical ... of its Medical Trade Shows & Conventions Calendar ... and equipment vendors. , The calendar is a continually-updating ... United States and around the world. Hundreds of entries ... is always growing. , Information listed on each trade ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... School of Engineering and Applied Science have taken a ... successfully using the bacterium Escherichia coli to ... polyketides, which include important antibiotic and anticancer drugs. ... potent chemical compounds produced by living organisms; many are ...
... 2008 The Women,s Heart Health Initiative at the ... a new fellowship dedicated to gender-specific research that will ... in women. The announcement will take place during a ... "Women face unique challenges to successful diagnosis and treatment ...
... offered the perfect job. The not-so-good news it,s ... people with diseases like HIV, or those who are simply ... a medical exam to qualify for a job can be ... brings excellent news. , Medical exams are often not an ...
... Women with deficiency at time of delivery had almost ... 22 (HealthDay News) -- Vitamin D deficiency greatly increases ... U.S. researchers report. , During the two-year study, Boston ... examined the relationship between vitamin D levels in pregnant ...
... oncology researcher Dr. Daniel Von Hoff, a member ... an in-depth look at the "lost opportunity" in ... biotechnology companies use the phase I trial to ... Hoff advocates that it can also provide valuable ...
... from overweight and obesity. This is the result of a ... Elisabeth Weber and her coauthors present the results in the ... Arztbl Int 2008; 105 [51-52]: 883-9). The doctors recorded ... children, but also their mother tongue. Their parents had to ...
Cached Medicine News:Health News:E. coli engineered to produce important class of antibiotic, anti-cancer drugs 2Health News:A simple questionnaire to replace a doctor's exam 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 3Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 4
... a plastic device that fits over a standard ... a minimum amount of reagent. , , ... between the coverplate and slide. The liquid ... is dispensed into the well. Its pressure ...
ISI Micro Brushes are available in a variety of French diameters. Made with stainless steel handles and nylon bristles, the ISI Micro Brushes will last through countless cleanings....
... ISI offers instrument cleaning brushes ... diameters and composition. The long, ... cannulas and tubing. The smallest ... micros. The brass and stainless ...
... Nest is the wall organizer with a complete ... of sizes and diameters. Made of tough, durable ... Brush Nest is the ultimate organizer. , The ... in a variety of lengths, diameters and composition.,The ...
Medicine Products: